INCAGN 1949

Drug Profile

INCAGN 1949

Alternative Names: INCAGN 01949; INCAGN1949

Latest Information Update: 25 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Agenus; Ludwig Institute for Cancer Research
  • Developer Agenus; Incyte Corporation
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action OX40 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 09 Aug 2017 Incyte plans a phase I/II trial for Cancer (Late-stage disease, Metastatic disease, Adjunctive therapy) in USA, Spain, Switzerland and United Kingdom (NCT03241173)
  • 01 Apr 2017 Pharmacodynamics and pharmacokinetics data from a preclinical trial in Solid tumours presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 14 Feb 2017 Incyte and Agenus amend licensing agreement from profit-sharing agreement to royalty bearing agreement
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top